Mar 14, 2024
Medicilon, a one-stop pharmaceutical preclinical research and development CRO can simultaneously meet Chinese and American drug discovery and development needs (including GLP standards) promptly and efficiently with fast initiation times.
Feb 29, 2024
On January 18, the Science and Technology Commission of Shanghai Municipality released the 2023 Shanghai Professional Technical Service Platform construction project list. There are only 29 platforms in Shanghai on the list.
Jan 08, 2024
Dr. Zhang Haizhou holds a PhD in Toxicology from Indiana University, USA. He is a pharmaceutical industry veteran with over 20 years of experience in the R&D of small and large molecule drugs.
Nov 29, 2023
Dr. Liu Jian, President of the Drug Discovery Division at Medicilon, has been awarded the Thomas Alva Edison Patent Award for 2023 from the New Jersey Research and Development Committee.
Jul 28, 2023
Medicilon, a one-stop pharmaceutical preclinical R&D service platform CRO, recognizes the importance of drug discovery as the cornerstone of new drug innovation. Recently, Medicilon appointed Dr. Liu Jian as the President of Drug Discovery Division.
Jun 26, 2023
On June 12, 2023, MindRank, which focuses on the use of AI to drive the development of new drugs, announced that the phase I clinical trial of its self-developed GLP-1RA small molecule oral drug MDR-001 successfully completed the first subject...
Jun 06, 2023
The China Biopharmaceutical Industry Chain Innovation Transformation Summit and the 3rd China Biopharmaceutical Innovation Billboard Awards Ceremony were grandly opened in Nanjing, China.
Apr 28, 2023
On April 20, Medicilon Preclinical Research (Shanghai) LLC (MPR), a wholly-owned subsidiary of Shanghai Medicilon Inc.
Apr 26, 2023
Shanghai Medicilon Inc. stood out from more than 1,500 outstanding companies and was successfully selected into the list of "2023 Shanghai Hardcore Technology Enterprises TOP 100 List".
Mar 22, 2023
On February 15, the Class 1 new drug Carenoprazan Hydrochloride Tablets, for the treatment of duodenal ulcer and reflux esophagitis, independently developed by Jiangsu Carephar Pharmaceutical (Carephar) was officially approved for sales in market.